Back to Search
Start Over
Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer † .
- Source :
-
Cancer investigation [Cancer Invest] 2020 Nov; Vol. 38 (10), pp. 608-617. Date of Electronic Publication: 2020 Oct 27. - Publication Year :
- 2020
-
Abstract
- Although physicians rely on clinical trial data to guide cancer treatment decisions, patient characteristics and outcomes often differ between real-world and clinical trial populations. We analyzed retrospective clinical data collected from a prior authorization (PA) tool linked with payer claims data to describe outcomes of first-line treatment for metastatic non-small cell lung cancer among 2,108 patients. Duration of therapy was shorter than observed in clinical trials. Healthcare costs and hospitalizations varied substantially by regimen. PA clinical data linked with administrative claims enable head-to-head comparisons of contemporary cancer treatments used in routine clinical practice, which are not available from clinical trials.
- Subjects :
- Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Non-Small-Cell Lung secondary
Female
Follow-Up Studies
Humans
Lung Neoplasms drug therapy
Lung Neoplasms pathology
Lymphatic Metastasis
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Non-Small-Cell Lung mortality
Lung Neoplasms mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1532-4192
- Volume :
- 38
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Cancer investigation
- Publication Type :
- Academic Journal
- Accession number :
- 33107767
- Full Text :
- https://doi.org/10.1080/07357907.2020.1827415